Nurix Therapeutics Reports $673.1 Million Revenue in Q3 2026, Driven by Roche Collaboration

Nurix Therapeutics, Inc. reported significant financial performance for the third quarter of 2026, with total revenue reaching $673.1 million, a substantial increase from $7.9 million in the same period last year. This growth was primarily driven by a one-time license revenue of $653.2 million recognized from the Roche Collaboration Agreement, alongside collaboration revenue of $19.9 million, which also saw an increase from $7.9 million year-over-year. For the nine months ending August 31, 2026, total revenue was $688.4 million, compared to $70.4 million in the prior year, reflecting a notable shift in the company's financial landscape.

The company’s operating expenses for the third quarter were $113.6 million, up from $99.3 million in the same quarter of 2025. This increase was attributed to higher general and administrative costs, which rose to $34.4 million from $13.2 million, largely due to one-time expenses related to the Roche transaction. Research and development expenses decreased slightly to $79.3 million from $86.1 million, reflecting cost-sharing arrangements under the Roche collaboration. The net income for the quarter was $549.8 million, a significant turnaround from a net loss of $86.4 million in the same quarter of the previous year.

In terms of operational developments, Nurix has made strides in its clinical pipeline, particularly with its lead candidate, bexobrutideg (NX-5948), which is currently in a Phase 2 study for chronic lymphocytic leukemia (CLL). The company has also entered into strategic collaborations with major pharmaceutical firms, including Gilead, Sanofi, and Pfizer, which have collectively provided substantial funding and support for its drug development efforts. As of August 31, 2026, Nurix had cash, cash equivalents, and marketable securities totaling $1.1 billion, positioning the company well for future operational needs.

The company’s employee headcount has also increased, reflecting its expansion efforts to support ongoing clinical trials and research initiatives. As of the latest report, Nurix has a total of 12,919,811 stock options outstanding and 2,765,459 restricted stock units, indicating a growing workforce aligned with its strategic goals. Looking ahead, Nurix anticipates continued investment in its clinical programs and infrastructure, with expectations of increased expenses as it advances its drug candidates through the development pipeline.

Management has indicated that while the current financial position is strong, the company will require additional funding to support its long-term business plan, particularly as it seeks to commercialize its drug candidates. The outlook remains cautiously optimistic, with the company planning to leverage its existing collaborations and explore new financing opportunities to sustain its growth trajectory in the competitive biopharmaceutical landscape.